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ABSTRACT
Sulbactam irreversibly inhibits the hydrolytic activity of b-lactamases. This compound is commercially
available in combination with either ampicillin or cefoperazone. In each instance, the activity of the
partner antibiotic against b-lactamase-producing bacteria is restored. One of the particular advantages of
using sulbactam-containing combinations is that sulbactam itself has inherent activity against some
Acinetobacter baumannii. Sulbactam combinations have not demonstrated strong selective pressures for
extended-spectrum b-lactamase-producing Enterobacteriaceae and vancomycin-resistant enterococci. In
contrast to clavulanate, sulbactam does not induce class I (Ampc) chromosomal b-lactamases in
Enterobacteriaceae.
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INTRODUCTION
b-Lactamase inhibitors are themselves b-lactam
antibiotics, usually with minimal or no antibac-
terial activity. When combined with certain
b-lactam antibiotics, they augment the potency
of these against b-lactamase-producing bacteria.
Three b-lactamase inhibitors (sulbactam, clavula-
nate and tazobactam) are commercially available.
Sulbactam is combined with either ampicillin or
cefoperazone and this review brieﬂy outlines the
in-vitro and clinical characteristics of these com-
binations.
CHEMICAL STRUCTURE AND
RELATED ACTIVITY
Sulbactam is chemically a penicillanic acid
sulphone and shows particular activity against
class A enzymes. However, compared with cla-
vulanate and tazobactam, sulbactam is a less
potent inhibitor of this class, particularly for
SHV-1 [1]. Against class C b-lactamases, sulbac-
tam is more potent than clavulanate, whereas
activity against class D enzymes is less potent
than against class A b-lactamases. Similarly,
OXA-type enzymes are not as well inhibited
by sulbactam as TEM-1 and other clinically used
inhibitors.
In general, b-lactamase inhibitors have negligi-
ble antimicrobial activity themselves, but restore
antimicrobial activity to other b-lactams when
used in combination. However, sulbactam is
exceptional in that it has intrinsic activity against
Acinetobacter spp. [2,3] and Bacteroides fragilis.
High-afﬁnity binding to penicillin-binding pro-
tein 2 of these organisms is responsible for this
activity [2].
Paradoxically, b-lactamase inhibitors, particu-
larly clavulanate, may induce production of
b-lactamases in some Gram-negative bacteria,
causing autagonism of their partner b-lactamases
[4]. No such activity has been described with
sulbactam [5].
IN-VITRO ACTIVITY
Early studies reported that more than 90% of
strains, among a variety of organisms, were
inhibited at £4 mg ⁄L with a ﬁxed ratio (1:2) of
sulbactam and ampicillin [6]. These included
methicillin-susceptible Staphylococcus aureus,
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Staphylococcus epidermidis, B. fragilis, Haemophilus
inﬂuenzae, Moraxella catarrhalis, Escherichia coli,
Klebsiella pneumoniae and Proteus spp. However,
recent trials have indicated increasing resistance
to sulbactam–ampicillin. In a study with a total of
3134 aerobic and facultative Gram-negative bacil-
li, sulbactam–ampicillin was the least active agent
among the 12 antibiotics tested against E. coli and
Klebsiella spp., with susceptibility rates of 56%
and 73%, respectively [7]. Extended-spectrum b-
lactamases (ESBLs) were detected in 7% of E. coli
and 13% of Klebsiella spp. isolates.
In the absence of CLSI criteria, in-vitro stud-
ies have used cefoperazone breakpoints for
reporting the susceptibility results for sulbac-
tam–cefoperazone. Thus, resistance was deﬁned
as ‡64 mg ⁄L with a ﬁxed ratio (2:1) of cefope-
razone and sulbactam (the latter was used at
8 mg ⁄L), intermediate susceptibility as
32 ⁄ 16 mg ⁄L and susceptibility as <16 ⁄ 8 mg ⁄L
[8]. Studies with large numbers of Gram-
positive and -negative strains revealed suscepti-
bility in methicillin-susceptible Staphylococcus
aureus, Enterobacteriaceae, anaerobic bacteria,
including B. fragilis, and various non-fermenters,
including Pseudomonas aeruginosa and Acinetobac-
ter spp. [9]. Higher MIC values were reported
for ESBL-producing strains [10].
Substantial in-vitro susceptibility to both sul-
bactam combinations has been shown in Acineto-
bacter spp., including carbapenem-resistant
strains [11]; however, increasing resistance has
also been reported. A recent trial from Turkey
reported results concerning 1196 Gram-negative
clinical isolates, mostly cultured from blood
(n = 323), urine (n = 548) and respiratory
secretions (n = 152). Susceptibility to sulbactam–
cefoperazone, piperacillin–tazobactam, imipe-
nem, ceftriaxone, ceftazidime and cefepime was
determined by Etest in E. coli (n = 457, 26% ESBL-
positive), K. pneumoniae (390, 32% ESBL-positive),
P. aeruginosa (194) and Acinetobacter baumannii
(155). Resistance in these isolates to sulbactam–
cefoperazone was 6%, 17.7%, 27.9% and 41.3%,
respectively. Sulbactam–cefoperazone was the
most active drug against A. baumannii and the
second most active, only after imipenem, against
E. coli and K. pneumoniae; it was the third most
active drug against P. aeruginosa, after imipenem
and piperacillin–tazobactam.
MECHANISMS OF RESISTANCE TO
INHIBITOR COMBINATIONS
The in-vitro and clinical efﬁcacies of b-lactamase
inhibitors have been compromised by the emer-
gence of resistant isolates during the last decade.
The mechanisms involved in and responsible for
this resistance are multiple. Most bacteria with
derepressed class C b-lactamases are resistant to
inhibitor combinations. Overproduction of the
class A penicillinases TEM-1 and TEM-2, or pro-
duction of low-afﬁnity enzymes such as inhibitor-
resistant TEM and the OXA enzymes, are other
mechanisms of resistance. Overproduction of b-
lactamases is due to either a point mutation in the
promoters for the genes encoding TEM-1 and
TEM-2 or to multicopy, plasmid-borne genes [12].
PHARMACOKINETICS
The pharmacokinetic parameters of sulbactam
combinations are shown in Tables 1 and 2 [13,14].
Oral absorption of sulbactam is very poor. How-
ever, a double-ester prodrug, in combination with
ampicillin (sultamicillin), allows up to 68%
absorption [15]. Sulbactam is mainly excreted
via kidneys, with 75% of the dose being recov-
ered in the urine in the ﬁrst 8–12 h [13]. Therefore,
its clearance is signiﬁcantly decreased in patients
with renal failure. Haemodialysis removes 30% of
the given doses of sulbactam–ampicillin, and
Table 1. Pharmacokinetic proper-
ties of intravenous sulbactam–ampi-
cillin in healthy adults [13]
Alone Combined
Ampicillin Sulbactam Ampicillin Sulbactam
Cmax (lg ⁄h ⁄mL) 27.6 31.8 23.2 30.4
AUC (lg ⁄h ⁄mL) 30.3 29.6 24.7 36.6
t1/2 (h) 1.3 0.96 1.00 1.06
Cmax, maximum serum concentration of the drug; AUC, area under the
concentration curve; t1.2, serum half-life of the drug.
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supplemental doses are recommended after dial-
ysis [13]. However, only 4% of cefoperazone is
removed with the same intervention, and the
main route of excretion for this drug is via the
biliary tract. Thus, in patients with a creatinine
clearance of <30 mL ⁄min, if sulbactam is given
once-daily in combination with cefoperazone,
additional doses of cefoperazone alone are re-
quired every 12 h. Both sulbactam–ampicillin and
sulbactam–cefoperazone penetrate well into tis-
sue. However, cerebrospinal tissue penetration is
negligible with sulbactam–cefoperazone and
yields only 34% of the serum concentration with
sulbactam–ampicillin [13].
CLINICAL USAGE
Parenteral sulbactam–ampicillin has been widely
used in cases of community and ⁄ or hospital-
acquired pneumonia, including those due to
aspiration of oropharyngeal secretions, and
in several mixed infections, including intra-
abdominal infections, diabetic foot infections,
brain abscesses, staphylococcal bacteraemia,
outpatient sepsis and skin and soft-tissue infec-
tions, paediatric infections such as acute epiglot-
titis, and periorbital cellulitis [16–20]. In
neonates, exposure to sulbactam–ampicillin was
not signiﬁcantly associated with colonisation
with multidrug-resistant Gram-negative bacteria,
including ESBL producers [21].
Oral sulbactam–ampicillin is indicated in less
severe infections such as sinusitis, otitis media,
urinary tract infections and cellulitis, or as step-
down therapy for patients who have improved
under parenteral therapy.
Sulbactam–cefoperazone has been used in
several nosocomial infections, including mild-
to-moderate and severe nosocomial pneumonia,
intra-abdominal infections, including biliary sep-
sis, intra-abdominal abscesses, pelvic inﬂamma-
tory disease, gynaecological infections, sepsis,
infections in burn patients, and infections in
febrile neutropenic patients [2,18]. In a prospec-
tive controlled clinical trial, treatment with
sulbactam–cefoperazone for bacteraemia due to
CTX-M-type ESBL-producing E. coli was as suc-
cessful as that with imipenem or ceftazidime
[22].
On the other hand, despite in-vitro sensitivity
to sulbactam and other b-lactamase inhibitor
combinations, high failure rates in patients in-
fected with ESBL-positive bacteria have been
reported [23], most probably due to the concur-
rent presence of other resistance mechanisms in
the strains responsible for the infection.
ADVERSE EFFECTS
Both sulbactam combinations have favourable
safety proﬁles and are well-tolerated [2,13]. The
addition of sulbactam to either ampicillin or
cefoperazone does not compromise the safety of
these b-lactam antibiotics.
CONCLUSION
Owing to their in-vitro activity against several
aerobic and anaerobic bacteria, and their reliable
pharmacokinetic and safety proﬁles, sulbactam
combinations have been widely used for several
clinical indications. Among these, infections
caused by Acinetobacter spp., with or without
multidrug-resistant proﬁles, have become a
prominent indication. However, clinical efﬁcacy
is doubtful in the case of severe infections caused
by ESBL-producing bacteria and, as with the
other inhibitors, clinicians should be very cau-
Table 2. Pharmacokinetic properties of intravenous sulbactam–cefoperazone in healthy adults [14]
Cmax (mg ⁄L) V (L) AUC (lg ⁄h ⁄mL) t1.2 (h) CL (mL ⁄min) CLR (mL ⁄min)
Cefoperazone (day 7)
Alone (n = 14) 430 ± 44 11 ± 2 690 ± 82 1.8 ± 0.3 73 ± 9 21 ± 4
+ Sulbactam (n = 14) 431 ± 57 11 ± 1 679 ± 122 1.8 ± 0.3 76 ± 10 19 ± 3
Sulbactam (day 7)
Alone (n = 12) 91 ± 20 30 ± 8 80 ± 20 1.1 ± 0.1 331 ± 75 296 ± 74
+ Cefoperazone (n = 14) 92 ± 17 28 ± 6 85 ± 14 1.1 ± 0.2 301 ± 46a 262 ± 52b
V, volume of distribution; L, litres; CL, total body clearance; CLR, renal clearance.
ap 0.04 vs. administration alone.
bp 0.03 vs. administration alone.
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tious in using sulbactam combinations for infec-
tions due to these organisms.
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